NEREUS Launch NEREUS tradipitant is commercially available across the US as of May 1, 2026, marking the first new prescription for motion-induced vomiting in more than 40 years. This creates opportunities for strategic market access, payer negotiation, and multi-channel distribution partnerships, including specialty pharmacies, hospitals, and travel-related providers to maximize patient reach.

Growth Readiness With revenue in the $100–250 million range and a headcount of 501–1000, Vanda sits in a mid-market pharma tier that is conducive to outsourcing and partnerships for commercialization, manufacturing scale, and supply chain optimization as it expands its portfolio.

Market Leadership The launch positions Vanda as a leader in a niche GI/antiemetic space. This can support discussions around real-world evidence programs, payer formulary access, and potential expansion into adjacent indications or geographies through licensing or co-development deals.

Governance Signals Recent leadership changes, including the departure of the General Counsel and a new board member appointment, signal evolving governance dynamics. BD opportunities could include regulatory/compliance support, risk assessment for partnerships, and diligence for licensing or acquisition discussions.

Industry Engagement Active participation in life sciences conferences indicates openness to BD conversations. Leverage these events to initiate relationships with CROs, KOLs, payers, and potential licensing partners for co-development, distribution, or market access collaborations.